CytomX Therapeutics announced that the first clinical candidate in its TCB, T-Cell Engaging Bispecific, agreement with Astellas has entered into GLP toxicology studies which triggers a $5 million payment to CytomX. The clinical candidate is the first PROBODY TCB molecule under this alliance to progress into a GLP toxicology study. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs with CytomX eligible to receive future preclinical, clinical and commercial milestones. “We are excited by the continued momentum towards a potential future IND for the first PROBODY TCB clinical candidate in our collaboration with Astellas, and we continue to partner with Astellas on multiple preclinical programs. The progress with this collaboration highlights the benefits of our strategy to create value through both wholly-owned and partnered programs, as well as the potential of our expanding pipeline of PROBODY T-cell engagers which are designed to localize T-cell activity to the tumor microenvironment,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTMX:
- CytomX Therapeutics Braces for Increased Compliance Costs as it Outgrows ‘Smaller Company’ Status
- CytomX Therapeutics price target lowered to $3.25 from $3.30 at BMO Capital
- CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
- Options Volatility and Implied Earnings Moves Today, March 11, 2024
- Biotech Alert: Searches spiking for these stocks today